Posts

Posted on

Arcosa, Inc. Announces Pricing of $400 Million of 4.375% Senior Notes Due 2029

Arcosa, Inc. Announces Pricing of $400 Million of 4.375% Senior Notes Due 2029

DALLAS–(BUSINESS WIRE)–
Arcosa, Inc. (NYSE: ACA) (“Arcosa”), a provider of infrastructure-related products and solutions, today announced the pricing of its previously announced private offering of $400 million aggregate principal amount of 4.375% senior notes due 2029 (the “Notes”). The Notes offering is expected to close on April 6, 2021, subject to customary conditions.

Arcosa intends to use the net proceeds of the offering to fund the payment of the purchase price of the previously announced acquisition of StonePoint Ultimate Holding, LLC and affiliated entities (“StonePoint”), which is expected to close in April 2021, to repay any borrowings that may be outstanding under Arcosa’s $150 million 364-day credit facility at the closing of the offering of the Notes, and to use any remaining net proceeds for general corporate purposes, which may include repayment in whole, or in part, of amounts outstanding under its existing revolving credit facility and other potential strategic investments. The closing of the offering is not conditioned upon the completion of the StonePoint acquisition. The Notes will be senior unsecured obligations of Arcosa and will initially be guaranteed on a senior unsecured basis by each of Arcosa’s domestic subsidiaries that is a guarantor under its existing senior credit facility.

The Notes and the related guarantees are being offered and sold only to persons reasonably believed to be “qualified institutional buyers” in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to certain non-U.S. persons in compliance with Regulation S under the Securities Act. The Notes and the related guarantees have not been registered for sale under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, the Notes or any other securities, and shall not constitute an offer to sell, solicitation of an offer to buy, or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offers of the Notes will be made only by means of a private offering memorandum.

About Arcosa

Arcosa, Inc. (NYSE: ACA), headquartered in Dallas, Texas, is a provider of infrastructure-related products and solutions with leading positions in construction, engineered structures, and transportation markets. Arcosa reports its financial results in three principal business segments: Construction Products, Engineered Structures, and Transportation Products. For more information, visit www.arcosa.com.

Some statements in this release, which are not historical facts, are “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements about Arcosa’s estimates, expectations, beliefs, intentions or strategies for the future. Arcosa uses the words “anticipates,” “assumes,” “believes,” “estimates,” “expects,” “intends,” “forecasts,” “may,” “will,” “should,” “guidance,” “outlook,” “strategy,” and similar expressions to identify these forward-looking statements. Forward-looking statements speak only as of the date of this release, and Arcosa expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained herein, except as required by federal securities laws. Forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results to differ materially from historical experience or our present expectations, including but not limited to assumptions, risks and uncertainties regarding the completion of the StonePoint acquisition; the impact of the COVID-19 pandemic on Arcosa’s customer demand for Arcosa’s products and services, Arcosa’s supply chain, Arcosa’s employees’ ability to work because of COVID-19 related illness, the health and safety of our employees, the effect of governmental regulations imposed in response to the COVID-19 pandemic; assumptions, risks and uncertainties regarding achievement of the expected benefits of Arcosa’s spin-off from Trinity; tax treatment of the spin-off; market conditions and customer demand for Arcosa’s business products and services; the cyclical nature of, and seasonal or weather impact on, the industries in which Arcosa competes; competition and other competitive factors; governmental and regulatory factors; changing technologies; availability of growth opportunities; market recovery; ability to improve margins; risks and uncertainties related to the capital markets generally; whether Arcosa will consummate the offering; the anticipated terms of the Notes and the anticipated use of proceeds; and Arcosa’s ability to execute its long-term strategy, and such forward-looking statements are not guarantees of future performance. For further discussion of such risks and uncertainties, see “Risk Factors” and the “Forward-Looking Statements” section of “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Arcosa’s Form 10-K for the year-ended December 31, 2020, as may be revised and updated by Arcosa’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

INVESTOR CONTACTS

Scott C. Beasley

Chief Financial Officer

Gail M. Peck

SVP, Finance & Treasurer

T 972.942.6500

[email protected]

David Gold

ADVISIRY Partners

T 212.661.2220

[email protected]

MEDIA CONTACT

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Other Construction & Property Engineering Construction & Property Manufacturing

MEDIA:

Posted on

INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against SOS Limited

INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against SOS Limited

NEW YORK–(BUSINESS WIRE)–
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired SOS Limited (“SOS” or the “Company”) (NYSE: SOS) securities during the period from July 22, 2020, through February 25, 2021 (the “Class Period”). Investors have until June 1, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The lawsuit alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose to investors: (i) SOS had misrepresented the true nature, location, and/or existence of at least one of the principal executive offices listed in its SEC filings; (ii) HY and FXK were either undisclosed related parties and/or entities fabricated by the Company; (iii) the Company had misrepresented the type and/or existence of the mining rigs that it claimed to have purchased; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On February 26, 2021 Hindenburg Research (“Hindenburg”) and Culper Research (“Culper”) released commentary on SOS, claiming that the Company was an intricate “pump and dump” scheme that used fake addresses and doctored photos of crypto rigs to create an illusion of success.

On this news, the price of SOS’s American depositary share (“ADS”) declined by $1.27 per ADS, or approximately 21.03%, to close at $4.77 per ADS on February 26, 2021.

If you acquired SOS securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at [email protected], or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kirby McInerney LLP

Thomas W. Elrod, Esq., (212) 371-6600

[email protected]

www.kmllp.com

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma

– Sarclisa regimen reduced risk of disease progression or death by 45% compared to standard of care in patients who had relapsed after one to three prior therapies

– While the median progression free survival (PFS) for Sarclisa combination therapy is not yet reached, consistent improvement in PFS is seen across patient subgroups

– This is the second FDA approval for Sarclisa in combination with standard of care backbone therapies

PR Newswire

PARIS, March 31, 2021 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy.

“In the Phase 3 IKEMA study, the addition of Sarclisa to carfilzomib and dexamethasone reduced risk of disease progression or death by 45%,” said Thomas G. Martin, M.D., Associate Director, Myeloma Program, The University of California, San Francisco, Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program and co-leader of the Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center. “This approval is an important advancement for patients whose disease has relapsed and reinforces the potential for Sarclisa
to become a standard of care in relapsed or refractory multiple myeloma
.”

This marks the second FDA approval for Sarclisa, which is also approved in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with RRMM who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

“Treatment of patients with relapsed or refractory multiple myeloma remains challenging and the prognosis for patients experiencing multiple relapses unfortunately is poor,” said Peter C. Adamson, M.D., Global Development Head, Oncology and Pediatric Innovation at Sanofi. “With this approval, Sarclisa is now included in two standard of care regimens for the treatment of patients with multiple myeloma as early as first relapse. Today’s milestone further supports our ambition for Sarclisa to become the anti-CD38 of choice for patients with relapsed or refractory multiple myeloma.” 

Sarclisa Phase 3 IKEMA pivotal trial results supporting approval

The FDA approval is based on data from the Phase 3 IKEMA study, a randomized, multi-center, open label clinical trial that enrolled 302 patients with relapsed multiple myeloma across 69 centers spanning 16 countries.1 In this study, Sarclisa added to Kd (Sarclisa combination therapy) reduced the risk of disease progression or death by 45% (hazard ratio 0.548, 95% CI 0.366-0.822, p=0.0032) versus standard of care Kd alone in patients with multiple myeloma. The median progression free survival (PFS) for Sarclisa combination therapy was not reached at the time of the pre-planned interim analysis. This study enrolled a difficult-to-treat patient population, including those who are elderly, have high cytogenetic risk or renal impairment. Overall, demographic and disease characteristics at baseline were balanced between the two treatment groups.2

Secondary endpoints of the IKEMA trial assessed the overall response rate (ORR) for Sarclisa combination therapy compared to Kd, including complete response (CR) and very good partial response (VGPR). There was no statistically significant difference in ORR, which remained similar for each arm at 86.6% for the Sarclisa combination therapy versus 82.9% for Kd (p=0.3859). The rate of CR was 39.7% in the Sarclisa combination therapy arm and 27.6% in the Kd arm. The rate of VGPR was 33% for patients receiving Sarclisa combination therapy and 28.5% for patients receiving Kd.2 At the time of the interim analysis, overall survival (OS) data were still immature.3

The most frequent adverse reactions (occurring in 20% or more of patients) for Sarclisa versus the control arm were upper respiratory tract infection (67% vs. 57%), infusion-related reactions (46% vs. 3.3%), fatigue (42% vs. 32%), hypertension (37% vs. 32%), diarrhea (36% vs. 29%), pneumonia (36% vs. 30%), dyspnea (29% vs. 24%), bronchitis (24% vs. 13%), and cough (23% vs. 15%). Serious adverse reactions that occurred in more than 5% of patients who received Sarclisa combination therapy were pneumonia (25%) and upper respiratory tract infections (9%). Permanent discontinuation of treatment because of adverse reactions (Grade 1-4) occurred in 8% of patients treated with Sarclisa combination therapy, and 2.8% of patients discontinued due to an infection.2

Multiple Myeloma: an incurable blood cancer, with significant burden

Multiple Myeloma (MM) is the second most common hematologic malignancy4, affecting more than 130,000 patients in the United States; approximately 32,000 Americans are diagnosed with multiple myeloma each year.5 Despite available treatments, MM remains an incurable malignancy, and is associated with significant patient burden. Since MM does not have a cure, most patients will relapse. Relapsed MM is the term for when the cancer returns after treatment or a period of remission. Refractory MM refers to when the cancer does not respond or no longer responds to therapy.

About Sarclisa

Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity. CD38 is highly and uniformly expressed on the surface of MM cells, making it a potential target for antibody-based therapeutics such as Sarclisa.

This marks the second FDA approval for Sarclisa since March 2020 and comes more than three months ahead of the FDA’s target action date. In February, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for a second indication for Sarclisa, in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The use of Sarclisa in combination with Kd is not currently approved in the European Union (EU), but the final decision whether to expand the indication is expected from the European Commission in the coming months. In Europe, Sarclisa is indicated in combination with pom-dex for the treatment of adult patients with RRMM who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. Outside of the U.S. and the EU, Sarclisa is approved in Switzerland, Canada, Australia, Japan, Russia, the UAE, South Korea, Taiwan and Brazil in combination with pom-dex for the treatment of certain adults with RRMM.

Sarclisa continues to be evaluated in multiple ongoing Phase 3 clinical trials in combination with current standard and novel treatments across the MM treatment continuum. It is also under investigation for the treatment of other hematologic malignancies and solid tumors. The use of Sarclisa in these additional settings is currently under clinical investigation and its safety and efficacy have not been fully evaluated by any regulatory authority.

IMPORTANT SAFETY INFORMATION AND INDICATION FOR U.S. PATIENTS

What is SARCLISA?

SARCLISA is a prescription medicine used in combination with:

  • The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
  • The medicines carfilzomib and dexamethasone, to treat adults with multiple myeloma who have already received 1 to 3 lines of treatment and they did not work or are no longer working.

It is not known if SARCLISA is safe and effective in children.

Important Safety Information

Do not receive SARCLISA if you have a history of a severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA (see the list of ingredients in the full Prescribing Information).

Before receiving SARCLISA, tell your healthcare provider about all of your medical conditions, including if you:

  • Have heart problems, if your healthcare provider prescribes SARCLISA in combination with carfilzomib and dexamethasone for you.
  • Are pregnant or plan to become pregnant. SARCLISA may harm your unborn baby. You should not receive SARCLISA during pregnancy.
    • Females who are able to become pregnant should use an effective method of birth control during treatment and for 5 months after your last dose of SARCLISA. Talk to your healthcare provider about birth control methods that you can use during this time.
      Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with SARCLISA.
  • Are breastfeeding or plan to breastfeed. It is not known if SARCLISA passes into your breast milk. You should not breastfeed during treatment with SARCLISA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines.  Especially tell your healthcare provider if you have ever taken a medicine for your heart.

How will I receive SARCLISA?

  • SARCLISA will be given to you by your healthcare provider by intravenous (IV) infusion into your vein.
  • SARCLISA is given in treatment cycles of 28 days (4 weeks), together with either the medicines pomalidomide and dexamethasone, or carfilzomib and dexamethasone.
    • In cycle 1, SARCLISA is usually given weekly.
    • Starting in cycle 2, SARCLISA is usually given every 2 weeks.
  • If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
  • Your healthcare provider will give you medicines before each dose of SARCLISA to help reduce the risk of infusion reactions (make them less frequent and severe).

What are the possible side effects of SARCLISA?

SARCLISA may cause serious side effects, including:

  • Infusion reactions. Infusion reactions are common with SARCLISA and can sometimes be severe or life threatening.
    • Your healthcare provider will prescribe medicines before each infusion of SARCLISA to help decrease your risk for infusion reactions or to help make any infusion reaction less severe. You will be monitored for infusion reactions during each dose of SARCLISA.
    • Your healthcare provider may slow down or stop your infusion, or completely stop treatment with SARCLISA if you have an infusion reaction.

Get medical help right away if you develop any of the following symptoms of infusion reaction during or after an infusion of SARCLISA:

—  shortness of breath, wheezing, or trouble breathing
—  swelling of the face, mouth, throat, or tongue
—  throat tightness
—  palpitations
—  dizziness, lightheadedness, or fainting
—  headache
—  cough
—  rash or itching
—  nausea
—  runny or stuffy nose
—  chills

  • Decreased white blood cell counts. Decreased white blood cell counts are common with SARCLISA and certain white blood cells can be severely decreased. You may have an increased risk of getting certain infections, such as upper and lower respiratory tract infections and urinary tract infections.

    Your healthcare provider will check your blood cell counts during treatment with SARCLISA. Your healthcare provider may prescribe an antibiotic or antiviral medicine to help prevent infection, or a medicine to help increase your white blood cell counts during treatment with SARCLISA.

Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA.

  • Risk of new cancers. New cancers have happened in people during treatment with SARCLISA. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA.
  • Change in blood tests. SARCLISA can affect the results of blood tests to match your blood type. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA. Tell all of your healthcare providers that you are being treated with SARCLISA before receiving blood transfusions.
  • Heart failure. Heart failure can happen during treatment with SARCLISA in combination with carfilzomib and dexamethasone. Tell your healthcare provider right away if you develop any of the following symptoms:

– trouble breathing

– cough

– swelling of your ankles, feet, or legs

The most common side effects of SARCLISA in combination with pomalidomide and dexamethasone include:

  • lung infection (pneumonia)
  • decreased red blood cell counts (anemia)
  • upper respiratory tract infection
  • decreased platelet counts (thrombocytopenia)
  • diarrhea

The most common side effects of SARCLISA in combination with carfilzomib and dexamethasone include:

  • upper respiratory tract infection
  • tiredness and weakness
  • high blood pressure
  • diarrhea
  • lung infection (pneumonia)
  • trouble breathing
  • trouble sleeping
  • bronchitis
  • cough
  • back pain
  • decreased red blood cells (anemia)
  • decreased platelet counts (thrombocytopenia)           

These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider or pharmacist.

Please see full

Prescribing Information

, including Patient Information


About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life


Media Relations Contact 


Sally Bain

Tel.: +1 (781) 264-1091


[email protected]


Investor Relations Contacts – Paris


Eva Schaefer-Jansen

Arnaud Delepine


Investor Relations Contacts – North America


Felix Lauscher

Fara Berkowitz

Suzanne Greco


IR main line:


Tel.: +33 (0)1 53 77 45 45


[email protected]



https://www.sanofi.com/en/investors/contact



Sanofi Forward-Looking Statements


This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

1 Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA). NCT03275285. Retrieved from: https://clinicaltrials.gov/ct2/show/NCT03275285
2 Sarclisa Prescribing Information. March 2020.
3 Moreau et. al. Isatuximab Plus Carfilzomib And Dexamethasone Vs Carfilzomib And Dexamethasone In Relapsed/Refractory Multiple Myeloma (Ikema): Interim Analysis Of A Phase 3, Randomized, Open-Label Study. Oral presentation at European Hematology Association Virtual Congress 2020. June 12, 2020
4 Kazandjian. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676-681. doi:10.1053/j/seminoncol.2016.11.004
5 National Cancer Institute. Myeloma Cancer Stat Facts. Available at: www.seer.cancer.gov/statfacts/html/mulmy.html. Accessed on February 22, 2021.

Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)  

 

Cision View original content:http://www.prnewswire.com/news-releases/fda-approves-sarclisa-isatuximab-irfc-in-combination-with-carfilzomib-and-dexamethasone-for-patients-with-relapsed-or-refractory-multiple-myeloma-301260109.html

SOURCE Sanofi

Posted on

Actinium to Participate in the Cell & Gene Meeting on the Mediterranean

– Actinium to highlight Iomab-ACT program for targeted conditioning for CAR-T, adoptive cell therapies, and gene therapies

– Iomab-ACT intended to displace non-targeted chemotherapy based conditioning regimens

PR Newswire

NEW YORK, March 31, 2021 /PRNewswire/ — Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that it will be participating in the Cell & Gene Meeting on the Mediterranean, which is being held virtually April 6 – 9, 2021, where it will feature its Iomab-ACT program. Iomab-ACT is an extension of Actinium’s lead program, Iomab-B, which is being studied in a pivotal Phase 3 trial for targeted myeloablative conditioning prior to a bone marrow transplant. Iomab-ACT uses a lower dose of radiation, intended to achieve lymphodepletion for CAR-T and other adoptive cell therapies or reduced intensity conditioning for gene therapies.

Iomab-ACT is being utilized in a clinical collaboration with Memorial Sloan Kettering Cancer Center (“MSK”) for targeted conditioning with MSK’s CD19 targeting CAR T-cell therapy 19-28z for patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Actinium and MSK were jointly awarded National Institutes of Health Small Business Technology Transfer grant funding for this first ever trial to evaluate ARC-based targeted conditioning prior to CAR-T therapy. In addition, Actinium is collaborating with University California, Davis to use Iomab-ACT for targeted conditioning with UC Davis’ anti-HIV stem cell gene therapy for patients with HIV-related lymphoma.

Conference participants interested in meeting with Actinium can do so through the partneringONE™ system https://informaconnect.com/cell-gene-meeting-on-the-mediterranean/pone/login/ or by contacting Eileen Geoghegan, Ph.D., Associate Director, Strategic Research & Business Development by email at [email protected].

About the Cell & Gene Meeting on the Mediterranean

The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the entire cell and gene therapy community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector, this program features expert-led panels, extensive one-on-one partnering capabilities, exclusive networking opportunities, and 50+ dedicated presentations by leading publicly traded and privately held companies in the space. 

About Iomab-ACT

Iomab-ACT targets cells that express CD45, an antigen found on immune cells such as lymphocytes and macrophages as well as leukemia and lymphoma cancer cells and delivers the radioisotope warhead iodine-131 to achieve cell depletion.  Iomab-ACT is intended to deplete CD45+ immune cells such as macrophages that are implicated in CAR-T related toxicities and may also have an anti-tumor effect on chemo-refractory cancers.  Iomab-ACT is a low dose extension of Actinium’s lead program, Iomab-B, which is being studied in a pivotal Phase 3 trial for targeted conditioning prior to a bone marrow transplant. Preclinical data supporting Iomab-ACT’s application in targeted lymphodepletion prior to ACT such as CAR-T was recently published in the journal Oncotarget (https://www.oncotarget.com/archive/v11/i39/).  

In addition, clinical data with trace doses of Iomab-B has shown transient, reversible lymphodepletion in patients and drug clearance pharmacokinetics that fit within the vein-to-vein time of CAR-T manufacturing and administration.

About Actinium Pharmaceuticals, Inc. (NYSE: ATNM)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.  Actinium’s lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities.  With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently.  Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning.  The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings.  Iomab-ACT (low dose I-131 apamistamab) is also be studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy with Memorial Sloan Kettering Cancer Center and is intended to be studied for conditioning prior to gene therapy.  In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.  Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax.  Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform.  This is where our intellectual property portfolio of over 140 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes.  Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. Website: https://www.actiniumpharma.com/

Forward-Looking Statements for Actinium Pharmaceuticals, Inc. 

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Contacts:

Hans Vitzthum

LifeSci Advisors, LLC
[email protected] 
(617) 430-9758

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/actinium-to-participate-in-the-cell–gene-meeting-on-the-mediterranean-301260108.html

SOURCE Actinium Pharmaceuticals, Inc.

Posted on

Lonestar Resources to Present at EnerCom Dallas Conference

Lonestar Resources to Present at EnerCom Dallas Conference

FORT WORTH, Texas–(BUSINESS WIRE)–
Lonestar Resources US Inc. (OTC: LONE) (together with its subsidiaries, “Lonestar” or the “Company”) announced today that the Company will be presenting at the EnerCom Dallas Energy Investment & ESG Conference. Lonestar will present to investors at 8:50 AM Central Daylight Time on Tuesday, April 6th, 2021.

The EnerCom Dallas event will be hosted in a hybrid format with a small (100 – 150 people) in person audience on April 6th in Dallas at the Petroleum Club (still webcast out to the larger registered virtual audience) and a full virtual day of presentations and panel discussions on April 7th.

About Lonestar

Lonestar is an independent oil and natural gas company, focused on the development, production and acquisition of unconventional oil, natural gas liquids and natural gas properties in the Eagle Ford Shale in Texas.

Cautionary Note Regarding Forward-Looking Statements

Disclosures in this press release contain certain forward-looking statements within the meaning of the federal securities laws. Statements that do not relate strictly to historical or current facts are forward-looking. These statements contain words such as “possible,” “if,” “will,” “expect” and “assuming” and involve risks and uncertainties including, among others that our business plans may change as circumstances warrant and securities of the Company may not ultimately be offered to the public because of general market conditions or other factors. Accordingly, readers should not place undue reliance on forward-looking statements as a prediction of actual results. For more information concerning factors that could cause actual results to differ materially from those conveyed in the forward-looking statements, please refer to the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2021 and any subsequently filed quarterly reports on Form 10-Q. Any forward-looking statements in this press release are made as of the date of this press release and the Company undertakes no obligation to update or revise such forward-looking statements to reflect events or circumstances that occur, or of which the Company becomes aware, after the date hereof, unless required by law.

Chase Booth, 817-921-1889

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Oil/Gas Energy

MEDIA:

Logo
Logo
Posted on

Consolidated Water Reports 2020 Revenue up 6% to $72.6 Million

GEORGE TOWN, Cayman Islands, March 31, 2021 (GLOBE NEWSWIRE) — Consolidated Water Co. Ltd. (Nasdaq Global Select Market: CWCO), a leading developer and operator of advanced water supply and treatment plants, reported results for the year ended December 31, 2020. All annual comparisons are to the previous year unless otherwise noted.

2020 Highlights

  • Revenue increased 6% to a record $72.6 million.
  • Services segment revenue increased to $12.9 million, with $12.5 million of the revenue due to acquiring a 51% controlling interest in PERC Water in October 2019.
  • Services segment gross profit was $3.2 million versus $0.5 million in 2019.
  • Net income from continuing operations attributable to stockholders was $8.6 million or $0.56 per diluted share.
  • Cash and cash equivalents totaled $43.8 million as of December 31, 2020.
  • Paid $5.1 million in dividends.
  • Acquired an additional 10% of PERC Water in October 2020, increasing the company’s ownership to 61%.
  • Acquired the remaining 49% interest in Aerex Industries, Consolidated Water’s specialty manufacturer of water treatment-related systems and products, in January 2020.

Management Commentary

“In 2020 we increased total revenue by 6% to a record $72.6 million, generated net income of $8.6 million and paid $5.1 million in dividends – all despite the unprecedented challenges caused by the global pandemic,” said Consolidated Water’s CEO, Rick McTaggart. “Our services segment, led by our PERC Water subsidiary, performed well during economic weakness in its marketplace. We expect PERC’s strong performance, including the expansion of its recurring revenue stream from operating and maintenance contracts, to continue in 2021.

“We are currently in discussions with existing and potential clients in California that are seeking cost-effective solutions to their wastewater treatment and potable water challenges. We believe that the pandemic has adversely effected the finances of many communities across our service areas and they are increasingly looking for innovative public-private partnership arrangements to address their water challenges. PERC’s excellent reputation and strong track record of successfully delivering projects through a wide range of project delivery models, including public-private partnerships, is very attractive to resource-conscious municipalities and private operators.

“We believe conditions in the design-build market are also improving and that project activity will increase significantly in 2021, which should prove quite positive for our PERC business.

“PERC’s potential clients include golf clubs in California that are seeking to replace expensive potable water with sustainable reclaimed wastewater for irrigating landscaping and courses. We believe that PERC’s award-winning water reuse plant designs provide a competitive advantage in this niche market.

“We have also been working to expand PERC’s business into central Florida. PERC has natural synergies with Aerex’s water infrastructure manufacturing capabilities and is leveraging Aerex’s client base and excellent reputation in the region.

“The operations of our manufacturing business have not been significantly affected by the pandemic. However, as previously mentioned, Aerex’s largest customer informed us last October that it expects to suspend its purchases until the first quarter of 2022 due to inventory management related factors. While there can be no guarantee, we anticipate this customer will resume purchasing by the first quarter of 2022.

“Meanwhile, we have been focused on diversifying Aerex’s revenue by increasing sales of other products that it manufactures for existing and potential new customers. Since last fall, Aerex has been awarded two contracts to manufacture equipment for municipal water treatment projects in Florida. Production is scheduled to begin in April for the first and in the third quarter for the second, with both beginning to contribute revenue in the second quarter of this year. While we do not typically disclose the value of awarded contracts, we can state that each of these contracts are worth more than $1 million. We view these contracts as important milestones in our strategy to diversify Aerex’s product offerings and customer base.

“We expect our manufacturing segment revenue to be down in the first part of 2021 as compared to last year, as these new contracts will not begin to generate revenue until the second quarter. Aerex is presently also targeting three additional potential manufacturing projects in Florida.

“We are finally seeing some new opportunities for bidding on seawater desalination projects in the Caribbean that we are currently evaluating. Through PERC, we are also actively pursuing potential acquisitions and have several irons in the fire. We are looking to complete at least one acquisition before the end of the year that will expand our U.S. footprint.

“Overall, from an operational and financial perspective, our company remains in very good shape. We have substantially no debt and more than ample liquidity and capital resources to continue to be a great partner for the customers we have the privilege to serve.

“Over the course of 2021, we plan to continue expanding our business through organic growth, acquisitions, and new projects, as we further develop and broaden our water solution offerings. Above all, we will continue to focus on business that will provide increasing value for our shareholders.”

2020 Financial Summary

Total revenue for the full year 2020 increased 6% to a record $72.6 million from $68.8 million in 2019. The increase was driven by an increase of $11.2 million in services, which was due to the addition of PERC Water to the company’s services segment in late October 2019. The increase in total revenue was partially offset by decreases of $3.5 million, $2.7 million, and $1.2 million in the revenue of the retail, bulk and manufacturing segments, respectively.

Retail revenue declined due to a 13% decrease in the volume of water sold by Cayman Water primarily as a result of the tourism restrictions which were in effect for the last nine months of 2020 on Grand Cayman Island. The company believes that its retail business will eventually return to normal, as the vaccine becomes more widely administered and tourism resumes in its Grand Cayman retail service area.

The decrease in bulk water revenue was due to two new water supply contracts that commenced in February and July of 2019 with the Water Authority-Cayman at lower per gallon rates than the contracts they replaced, as well as a decline in revenue of approximately $1.5 million from the company’s Bahamas operations arising from lower energy prices which correspondingly reduced the energy pass-through component of CW-Bahamas’ rates.

The decrease in manufacturing revenue from 2019 to 2020 was due to a decrease in orders in the fourth quarter of 2020. Aerex’s largest customer informed Aerex last October that it was suspending its purchases until the first quarter of 2022 due to inventory management related factors. The company anticipates that orders from this customer will resume in the first quarter of 2022; however, it can offer no assurances that orders from this major customer will resume.

Gross profit decreased 5.3% to $26.8 million in 2020 from $28.3 million in 2019, with gross margin as a percentage of revenue decreasing from 41% to 37% primarily as a result of the decline in revenue for the retail segment.

Net income from continuing operations attributable to stockholders decreased 20.9% to $8.6 million or $0.56 per diluted share, compared to $10.9 million or $0.72 per diluted share in 2019.

Cash and cash equivalents totaled $43.8 million as of December 31, 2020, as compared to $42.1 million as of December 31, 2019. The increase resulted primarily from net income generated from continuing operations and the sale of CW-Belize.

2020 Segment Results

                               
    Year Ended December 31, 2020
    Retail   Bulk   Services   Manufacturing   Total
Revenue   $ 22,952,370     $ 24,312,546   $ 12,937,859   $ 12,425,351   $ 72,628,126  
Cost of revenue     11,080,814       16,959,563     9,698,214     8,121,080     45,859,671  
Gross profit     11,871,556       7,352,983     3,239,645     4,304,271     26,768,455  
General and administrative expenses     12,879,445       1,260,062     2,834,917     1,460,474     18,434,898  
Gain on asset dispositions and impairments, net     2,965       7,213     3,801     18     13,997  
Income (loss) from operations   $ (1,004,924 )   $ 6,100,134   $ 408,529   $ 2,843,815     8,347,554  
Other income, net                             1,082,946  
Income before income taxes                             9,430,500  
Provision for income taxes                             86,724  
Net income from continuing operations                             9,343,776  
Income from continuing operations attributable to non-controlling interests                             730,005  
Net income from continuing operations attributable to Consolidated Water Co. Ltd. stockholders                             8,613,771  
Net loss from discontinued operations                             (4,902,243 )
Net income attributable to Consolidated Water Co. Ltd. stockholders                           $ 3,711,528  

                                   
    Year Ended December 31, 2019
    Retail   Bulk   Services   Manufacturing   Total
Revenue   $ 26,456,022     $ 26,986,108   $ 1,759,446   $ 13,592,075   $ 68,793,651  
Cost of revenue     11,611,165       18,606,805     1,215,193     9,086,140     40,519,303  
Gross profit     14,844,857       8,379,303     544,253     4,505,935     28,274,348  
General and administrative expenses     13,422,821       1,238,296     392,425     1,947,622     17,001,164  
Gain on asset dispositions and impairments, net     398,041       47,000     —     —     445,041  
Income from operations   $ 1,820,077     $ 7,188,007   $ 151,828   $ 2,558,313     11,718,225  
Other income, net                               786,552  
Income before income taxes                               12,504,777  
Provision for income taxes                               66,621  
Net income from continuing operations                               12,438,156  
Income from continuing operations attributable to non-controlling interests                               1,549,978  
Net income from continuing operations attributable to Consolidated Water Co. Ltd. stockholders                               10,888,178  
Net income from discontinued operations                               1,287,915  
Net income attributable to Consolidated Water Co. Ltd. stockholders                             $ 12,176,093  





Revenue by Geographic Region

             
    Year ended December 31, 
    2020   2019
Cayman Islands   $ 25,640,169   $ 30,327,139
Bahamas     21,654,153     23,114,860
Indonesia     —     131
United States     24,918,527     14,968,868
Revenues earned from management services agreement with OC-BVI     415,277     382,653
    $ 72,628,126   $ 68,793,651



Annual General Meeting of Shareholders

The company has set May 24, 2021 as the date of its Annual General Meeting of Shareholders to be held at 4:00 p.m. Eastern Daylight Time. The Annual General Meeting will be a “hybrid” meeting of shareholders, meaning shareholders will be able to attend the Annual General Meeting as well as vote during the live webcast of the meeting by visiting www.virtualshareholdermeeting.com/cwco2021 or attend the meeting in person at the offices of Aquilex, Inc., 5810 Coral Ridge Drive, Suite 220, Coral Springs, FL 33076. Holders of record of the company’s stock as of March 25, 2021 will be entitled to vote at the meeting.

Conference Call

Consolidated Water management will host a conference call to discuss these results, followed by a question-and-answer period.

Date: Thursday, April 1, 2021
Time: 11:00 a.m. Eastern time (8:00 a.m. Pacific time)
Toll-free dial-in number: 1-844-875-6913
International dial-in number: 1-412-317-6709
Conference ID: 10153293

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.

A replay of the call will be available after 1:00 p.m. Eastern time on the same day through April 8, 2021, as well as available for replay via the Investors section of the Consolidated Water website at www.cwco.com.

Toll-free replay number: 1-877-344-7529
International replay number: 1-412-317-0088
Replay ID: 10153293

About Consolidated Water Co. Ltd.

Consolidated Water Co. Ltd. develops and operates advanced water supply and treatment plants and water distribution systems. The company operates water production facilities in the Cayman Islands, The Bahamas and the British Virgin Islands and operates water treatment facilities in the United States. The company also manufactures and services a wide range of products and provides design, engineering, management, operating and other services applicable to commercial and municipal water production, supply and treatment, and industrial water and wastewater treatment. For more information, visit www.cwco.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “intend”, “expect”, “should”, “will” or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to (i) continued acceptance of the company’s products and services in the marketplace; (ii) changes in its relationships with the governments of the jurisdictions in which it operates; (iii) the outcome of its negotiations with the Cayman government regarding a new retail license agreement; (iv) the future financial performance of its subsidiary that manufactures water treatment-related systems and products and provides design, engineering, management, operating and other services applicable to commercial, municipal and industrial water production; (v) the collection of its delinquent accounts receivable in the Bahamas; (vi) its ability to integrate and profitably operate the company’s recently acquired subsidiary PERC Water Corporation; (vii) the possible adverse impact of the COVID-19 virus on the company’s business; and (viii) various other risks, as detailed in the company’s periodic report filings with the Securities and Exchange Commission (“SEC”). For more information about risks and uncertainties associated with the company’s business, please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections of the company’s SEC filings, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q, copies of which may be obtained by contacting the company’s Secretary at the company’s executive offices or at the “Investors – SEC Filings” page of the company’s website at http://ir.cwco.com/docs. Except as otherwise required by law, the company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
David W. Sasnett
Executive Vice President and CFO
Tel (954) 509-8200
[email protected]

Investor Relations Contact

Ron Both, CMA
Tel (949) 432-7566
[email protected]

CONSOLIDATED WATER CO. LTD.

CONSOLIDATED BALANCE SHEETS

               
  December 31, 
  2020   2019
ASSETS              
Current assets              
Cash and cash equivalents $ 43,794,150     $ 42,071,083  
Accounts receivable, net   21,483,976       22,953,659  
Inventory   3,214,178       3,287,555  
Prepaid expenses and other current assets   2,412,282       1,559,448  
Contract assets   516,521       1,677,041  
Current assets of discontinued operations   1,511,099       1,619,056  
Total current assets   72,932,206       73,167,842  
Property, plant and equipment, net   57,687,984       61,238,752  
Construction in progress   440,384       1,335,597  
Inventory, noncurrent   4,506,842       4,404,378  
Investment in OC-BVI   2,092,146       1,903,602  
Goodwill   13,325,013       13,325,013  
Intangible assets, net   4,148,333       5,040,000  
Operating lease right-of-use assets   1,329,561       1,811,516  
Other assets   1,926,594       2,120,708  
Long-term assets of discontinued operations   21,166,489       27,669,966  
Total assets $ 179,555,552     $ 192,017,374  
               
LIABILITIES AND EQUITY              
Current liabilities              
Accounts payable, accrued expenses and other current liabilities $ 2,856,127     $ 3,503,561  
Accounts payable – related parties   200,558       57,410  
Accrued compensation   1,434,106       1,821,395  
Dividends payable   1,300,022       1,292,187  
Current maturities of operating leases   455,788       688,540  
Current portion of long-term debt   42,211       17,753  
Contract liabilities   461,870       339,616  
Current liabilities of discontinued operations   188,434       178,382  
Total current liabilities   6,939,116       7,898,844  
Long-term debt, noncurrent   126,338       61,146  
Deferred tax liabilities   1,440,809       1,529,035  
Noncurrent operating leases   982,076       1,156,543  
Net liability arising from put/call options   690,000       664,000  
Other liabilities   362,165       75,000  
Long-term liabilities of discontinued operations   2,499       2,679,932  
Total liabilities   10,543,003       14,064,500  
Commitments and contingencies              
Equity              
Consolidated Water Co. Ltd. stockholders’ equity              
Redeemable preferred stock, $0.60 par value. Authorized 200,000 shares; issued and outstanding 31,068
and 33,751 shares, respectively		   18,641       20,251  
Class A common stock, $0.60 par value. Authorized 24,655,000 shares; issued and outstanding
15,143,683 and 15,049,608 shares, respectively		   9,086,210       9,029,765  
Class B common stock, $0.60 par value. Authorized 145,000 shares; none issued   —       —  
Additional paid-in capital   86,893,486       88,356,509  
Retained earnings   64,910,709       66,352,733  
Total Consolidated Water Co. Ltd. stockholders’ equity   160,909,046       163,759,258  
Non-controlling interests   8,103,503       14,193,616  
Total equity   169,012,549       177,952,874  
Total liabilities and equity $ 179,555,552     $ 192,017,374  



CONSOLIDATED WATER CO. LTD.

CONSOLIDATED STATEMENTS OF INCOME

             
    Year Ended December 31, 
    2020   2019
Total revenue   $ 72,628,126     $ 68,793,651  
Total cost of revenue (including purchases from related parties of $1,349,331 in 2020 and $10,295 in 2019)     45,859,671       40,519,303  
Gross profit     26,768,455       28,274,348  
General and administrative expenses     18,434,898       17,001,164  
Gain on asset dispositions and impairments, net     13,997       445,041  
Income from operations     8,347,554       11,718,225  
             
Other income (expense):            
Interest income     540,096       588,509  
Interest expense     (9,669 )     (1,332 )
Profit-sharing income from OC-BVI     135,675       16,200  
Equity in the earnings of OC-BVI     371,019       44,765  
Net unrealized gain (loss) on put/call options     (26,000 )     56,000  
Other     71,825       82,410  
Other income, net     1,082,946       786,552  
Income before income taxes     9,430,500       12,504,777  
Provision for income taxes     86,724       66,621  
Net income from continuing operations     9,343,776       12,438,156  
Income from continuing operations attributable to non-controlling interests     730,005       1,549,978  
Net income from continuing operations attributable to Consolidated Water Co. Ltd.
stockholders 		    8,613,771       10,888,178  
Gain on sale of discontinued operations     —       3,621,170  
Net loss from discontinued operations     (4,902,243 )     (2,333,255 )
Total income (loss) from discontinued operations     (4,902,243 )     1,287,915  
Net income attributable to Consolidated Water Co. Ltd. stockholders   $ 3,711,528     $ 12,176,093  
             
Basic earnings (loss) per common share attributable to Consolidated Water Co. Ltd.
common stockholders 		           
Continuing operations   $ 0.56     $ 0.72  
Discontinued operations     (0.32 )     0.09  
Basic earnings per share   $ 0.24     $ 0.81  
             
Diluted earnings (loss) per common share attributable to Consolidated Water Co.
Ltd. common stockholders 		           
Continuing operations   $ 0.56     $ 0.72  
Discontinued operations     (0.32 )     0.08  
Diluted earnings per share   $ 0.24     $ 0.80  
             
Dividends declared per common and redeemable preferred shares   $ 0.34     $ 0.34  
             
Weighted average number of common shares used in the determination of:            
Basic earnings per share     15,119,305       15,025,639  
Diluted earnings per share     15,223,955       15,137,076  



Posted on

Spring Cleaning: Four Steps to Re-Establishing a Clean and Safe Workplace

PR Newswire

WILMINGTON, Mass., March 31, 2021 /PRNewswire/ — Though many of our nation’s workplaces have been much quieter and far less trafficked in recent months due to COVID-19 restrictions, National Cleaning Week (March 28 – April 4) and the gradual return to normalcy and on-site, 40-hour work weeks bring new meaning and importance to the term “spring cleaning.”

In order to “keep the lights on” and prevent businesses from closing entirely, budget cuts and reduced spending during the pandemic became a necessity for many. And often those cuts and reductions came in the areas of facility hygiene and cleaning programs, as many companies transitioned to working remotely from home with fewer (or no) employees in their buildings. Accordingly, the needs for normally scheduled services were reduced, paused, or eliminated altogether.

But as COVID-19 vaccinations are being distributed and the health of the nation continues to improve, businesses are once again reopening, and employees are beginning the slow transition from working remotely to returning back to the office. As a result, a reliable, consistent facility service supply program and diligent attention to cleaning, sanitizing, and dust control will become a necessity—perhaps more so than ever before.

The following four steps serve as a good baseline for not only reopening in as safe and clean a manner as possible, but also for maintaining a facility service program that helps ensure the overall health of your facility, your employees, and your customers:

  1. Prevent dirt and moisture from entering the building. 

    Scraper and walk-off mats placed at entrances help remove and capture shoe grime and outside dirt before it can enter the building. Over one pound of dirt and contaminants can accumulate in one square yard of carpet in just one week, and vacuuming only removes about 10 percent of the dirt. If floor mats are not regularly deep cleaned, they can become a source of facility contamination, not a barrier to it.

    Soiled mats should be picked up for professional laundering service and returned on a regular schedule to help ensure consistent cleanliness throughout the year.

  2. Maintain the cleanliness of hard surfaces like counters, desks, walls, conference room tables, and floors, as they are proven transmission points of contact for bacteria, viruses, and other sickness-causing germs. 

    Sanitizing solutions like Purell’s surface spray disinfectant system and sanitizing wipes and UniFirst’s 128 E-FECTicide spray disinfectant are specially formulated to help neutralize and/or kill germs on surfaces, greatly reducing risks of transmission and employee sickness. They are also effective in helping to combat SARS-CoV-2 (coronavirus).

    Contemporary cotton-based and technologically advanced microfiber floor mops, towels, and surface wipers are also specially designed to clean more effectively, trapping and holding contaminants and providing a “cleaner clean” than more traditional floorcare and wiping products, thereby reducing labor time and costs. Like floor mats, these products should be picked up regularly for professional laundering by a qualified facility services provider to maintain their effectiveness.

  3. Equip your
    workplace with essential restroom and ancillary products. 

    High-quality soaps and hand sanitizers, hand care products, and paper towels in portion-controlled dispensers made available to employees and customers are essential to maintaining proper hand hygiene. Most products are also available with touch-free dispenser options, adding an extra layer of protection between users and potential germ-transmitting surfaces. Hand sanitizer dispensers—either wall-mounted or on stands—should also be placed in common and high-traffic areas throughout building(s), making access to effective hand care that much more convenient for users.

    When combined with regular cleaning and a comprehensive offering of bathroom products, ancillary products such as toilet paper, air fresheners, trash can liners, and more, also show your employees and customers that you take hygiene, cleaning, and restroom appearance seriously.

  4. Contract with a qualified provider to regularly service, inspect, deliver, and maintain facility service product inventories and equipment. 

    On a regular schedule, a reputable service provider should pick up, launder, and deliver fresh floor mats, mops, and textiles, restock all required ancillary product inventories, inspect all dispensers, ensure that all equipment is in proper working order, and replace all items as needed.

According to UniFirst Director of Marketing and Communications Adam Soreff, “Qualified facility service providers like UniFirst take much of the guesswork out of building maintenance and hygiene and can also help businesses save money on routine product and service purchases.” He continues, “Regularly scheduled visits from a route service representative ensure that customers always have all the products they need on hand when they need them, and that all equipment is in perfect working order to help maintain the safest and cleanest work environments possible.”

Contracting services with a reputable provider like UniFirst is a big step towards providing peace of mind for your employees and customers as they return to your place of business. (Re)establishing scheduled services helps to ensure that you’re welcoming them back to a consistently clean, safe, and sanitized environment.

About UniFirst: 

Headquartered in Wilmington, Mass., UniFirst Corporation (NYSE: UNF) is a North American leader in the supply and servicing of uniform and workwear programs, as well as the delivery of facility service programs. Together with its subsidiaries, the company also provides first aid and safety products, and manages specialized garment programs for the cleanroom and nuclear industries. UniFirst manufactures its own branded workwear, protective clothing, and floorcare products; and with 260 service locations, over 300,000 customer locations, and 14,000 employee Team Partners, the company outfits more than 2 million workers each business day. For more information, contact UniFirst at 800.455.7654 or visit UniFirst.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/spring-cleaning-four-steps-to-re-establishing-a-clean-and-safe-workplace-301260106.html

SOURCE UniFirst Corporation

Posted on

BOA Acquisition Corp. Announces the Separate Trading of Its Class A Common Stock and Warrants, Commencing on March 31, 2021

BOA Acquisition Corp. Announces the Separate Trading of Its Class A Common Stock and Warrants, Commencing on March 31, 2021

WASHINGTON–(BUSINESS WIRE)–
BOA Acquisition Corp. (NYSE:BOAS.U) (“BOAS” or the “Company”) announced that holders of the units sold in the Company’s initial public offering of 23,000,000 units completed on February 26, 2021 (the “offering”) may elect to separately trade the shares of Class A common stock and warrants included in the units commencing on March 31, 2021. Any units not separated will continue to trade on The New York Stock Exchange under the symbol “BOAS.U”, and each of the shares of Class A common stock and warrants will separately trade on The New York Stock Exchange under the symbols “BOAS” and “BOAS WS,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their broker contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into shares of Class A common stock and warrants.

The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

The units were initially offered by the Company in an underwritten offering. BTIG, LLC acted as sole book-running manager and I-Bankers Securities, Inc. acted as co-manager in the offering.

The offering was made only by means of a prospectus, copies of which may be obtained on the U.S. Securities and Exchange Commission website at http://www.sec.gov. Alternatively, copies of the prospectus may be obtained from BTIG, LLC, 65 East 55th Street, New York, NY 10022, or by e-mail at [email protected].

A registration statement relating to the securities became effective on February 23, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any State or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State or jurisdiction.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute “forward-looking statements,” including with respect to the search for an initial business combination. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of BOAS, including those set forth in the Risk Factors section of the Company’s registration statement for BOAS’s initial public offering filed with the Securities and Exchange Commission (“SEC”). Copies are available on the SEC’s website, www.sec.gov. BOAS undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Jason Chudoba, 646-277-1249

[email protected]

or

Megan Kivlehan, 646-677-1807

[email protected]

KEYWORDS: United States North America District of Columbia

INDUSTRY KEYWORDS: Professional Services Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Finance Construction & Property Banking

MEDIA:

Posted on

Comerica Bank’s California Index Improves

PR Newswire

DALLAS, March 31, 2021 /PRNewswire/ — Comerica Bank’s California Economic Activity Index increased in January to a level of 108.9. January’s reading is 21 percent above the historical low of 90.2 set in June 2020. The index averaged 105.5 points in 2020, 18.8 points below the average for all of 2019. December’s index reading was revised to 106.8.

Our California Economic Activity Index rose again in January, marking its seventh consecutive monthly gain. The underlying data was less positive than the headline number. Multiple sectors were likely adversely impacted by statewide social mitigation restrictions which were still in place for most of January. Five of the eight index components were negative in January including nonfarm employment, housing starts, industrial electricity demand, state total trade and hotel occupancy. The index was pulled higher for the month due to strong improvements in unemployment insurance claims (inverted), house prices and the Dow Jones Technology Index. California house prices in particular are experiencing strong appreciation due to solid demand and low levels of available single-family houses on the market. Despite a challenging start to 2021, the outlook remains positive for the state economy. California household incomes will be supported this spring by both a recovering labor market and recently passed stimulus bills which included extended unemployment benefits and direct payments to households. The acceleration in the vaccine rollout this spring improves the probability of a wider reopening of the state economy as we head into the summer months. We expect to see a pickup in business activity as regions move out of the more restrictive social mitigation tiers and businesses expand capacity to keep up with strong demand.

The California Economic Activity Index consists of eight variables, as follows: nonfarm payroll employment, continuing claims for unemployment insurance, housing starts, house price index, industrial electricity sales, total trade, technology stock index and hotel occupancy. All data are seasonally adjusted. Nominal values have been converted to constant dollar values. Index levels are expressed in terms of three-month moving averages.

Comerica Incorporated (NYSE: CMA) is a financial services company headquartered in Dallas, Texas, and strategically aligned by three business segments: The Commercial Bank, The Retail Bank, and Wealth Management. Comerica focuses on relationships, and helping people and businesses be successful. In addition to Texas, Comerica Bank locations can be found in Arizona, California, Florida and Michigan, with select businesses operating in several other states, as well as in Canada and Mexico. Comerica reported total assets of $88 billion as of Dec. 31, 2020.

To subscribe to our publications or for questions, contact us at [email protected]. Archives are available at http://www.comerica.com/insights. Follow us on Twitter: @Comerica_Econ.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/comerica-banks-california-index-improves-301260074.html

SOURCE Comerica Bank

Posted on

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Sequential Brands Group, Inc. Investors With Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action – SQBG

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sequential Brands Group, Inc. (NASDAQ: SQBG) between November 3, 2016 and December 11, 2020, inclusive (the “Class Period”), of the important May 17, 2021lead plaintiff deadline.

SO WHAT: If you purchased Sequential securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Sequential class action, go to https://www.rosenlegal.com/cases-register-2006.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) in late 2016, Sequential knew or should have known that its goodwill was likely impaired; (2) Sequential avoided and delayed the material write down to goodwill in late 2016 through 2017; (3) Sequential understated its operating expenses and net loss and also materially overstated its income from operations, goodwill, and assets from late 2016 through 2017; (4) Sequential’s internal controls were deficient; (5) Sequential has failed to restate, correct, or disclose relevant improprieties, deceptive conduct, misstatements, omissions, and control violations; (6) as a result of the foregoing, Sequential was at greater risk of regulatory scrutiny and enforcement; and (7) as a result, defendants’ statements about Sequential’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Sequential class action, go to https://www.rosenlegal.com/cases-register-2006.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com